Medical Information
India
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for India Healthcare Professionals. Would you like to proceed?

I am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in IndiaYes, I am a healthcare professional
I am a patient/caregiver residing in IndiaNo, go back to the patient portal
SelectI am a patient/caregiver residing in IndiaNo, go back to the patient portal
Non-India residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Oral Presentation
Powles T, Sridhar SS, Bellmunt J, Sternberg CN, Grivas P, Hunter E, Dezfouli M, Salter M, Powel R, Ding A, Green J, Akoulitchev A, Amezquita R, Ching K, Pu J, Deng S, di Pietro A, Davis CB September 10, 2022 ESMO 2022 Urothelial Cancer

Genomic Biomarkers in Peripheral Blood (PB) From Patients (Pts) Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-Line (1L) Maintenance in Advanced Urothelial Carcinoma (aUC)

View Presentation
Poster
Aragon-Ching JB, Grivas P, Loriot Y, Bellmunt J, Wang J, Michelon E, di Pietro A, Powles T, Sridhar SS September 12, 2022 ESMO 2022 Urothelial Cancer

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From Patients With ≥12 Months of Treatment in JAVELIN Bladder 100

View Presentation View Abstract Plain Language Summary
Poster
Lapuente M, Milloy N, Berry M, Montgomery R, Bleasdale C, Kluth C, Kirker M, Kearney M, Costa N, Chang J September 12, 2022 ESMO 2022 Urothelial Cancer

Evaluating Real-World Caregiver Involvement From a Survey of Patients With Metastatic Urothelial Cancer (mUC) Receiving Systemic Anticancer Treatment in France, Germany, Italy, Spain, and the UK (Eu5)

View Presentation
Poster
Barthelemy P, Thibault C, Voog E, Eymard JC, Ravaud A, Flechon A, Abraham C, Hilgers W, Le Moulec S, Chasseray M, Pouessel D, Amela E, Lorgis V, Nicolas E, Kazan E, Denechere G, Solbes M-N, Lambert P, Loriot Y September 12, 2022 ESMO 2022 Urothelial Cancer

Preliminary Results From AVENANCE, an Ongoing, Noninterventional Real-World, Ambispective Study of Avelumab First-Line Maintenance Treatment in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

View Presentation View Abstract Plain Language Summary
Oral Presentation
Eto M, Desai C, Park SH, Tsuchiya N, Su P-J, Chan TTW, Gurney H, Gao S, Wang J, Sandner R, di Pietro A, Lee J-L December 2, 2022 ESMO Asia Urothelial Cancer

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Longer-Term Follow-Up From the Asian Subgroup of the JAVELIN Bladder 100 Trial

View Presentation View Abstract Plain Language Summary
Poster
Milloy N, Berry M, Montgomery R, Kluth C, Bleasdale C, Kirker M, Kearney M, Mohamed W, Costa N, Chang J December 3, 2022 ESMO Asia Urothelial Cancer

First-Line (1L) Treatment Patterns and Criteria Used to Determine Platinum Eligibility (PE) in Platinum-Eligible and -Ineligible Patients With Metastatic Urothelial Cancer (mUC) in South Korea and Taiwan

View Presentation